CDC184: A Potential Drug Target and Biomarker for Various Diseases

Target Name: CCDC184

NCBI ID: G387856

CCDC184

CDC184: A Potential Drug Target and Biomarker for Various Diseases

CCDC184 (C12orf68) is a gene that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique genetic mutation has led to a gain of function in the gene, resulting in the production of a hyperactive form of the protein.

The CCDC184 gene is located on chromosome 12 and encodes for the protein C12orf68. This protein plays a critical role in the regulation of cell growth, cell division, and apoptosis, which are all essential processes that are regulated by the immune system.

The CCDC184 gene has been identified as a potential drug target due to its involvement in the development and progression of various diseases, including cancer. Studies have shown that individuals with the CCDC184 genetic mutation are at an increased risk of developing malignant tumors, including breast, ovarian, and prostate cancers.

One of the key reasons for the potential drug targeting of CCDC184 is its involvement in the regulation of cell apoptosis, which is the process by which cells undergo programmed cell death. Unfortunately, in some individuals with the CCDC184 mutation, the regulation of cell apoptosis is disrupted, leading to the development of cancer.

Another potential drug target for CCDC184 is its role in the regulation of cell growth and division. Studies have shown that individuals with the CCDC184 mutation have altered levels of the protein PDGFR-尾, which is a critical regulator of cell growth and division. This altered regulation of cell growth and division can lead to the development of cancer.

In addition to its potential as a drug target, CCDC184 has also been identified as a potential biomarker for various diseases. The CCDC184 protein is expressed in a wide range of tissues and cells, including cancer cells, which makes it an attractive target for diagnostic tools.

Studies have shown that individuals with the CCDC184 mutation have altered levels of the CCDC184 protein, which can be detected in various body fluids, including blood, saliva, and urine. Additionally, studies have shown that the CCDC184 protein is overexpressed in various cancer types, which can be used as a biomarker for cancer diagnosis and monitoring.

In conclusion, CCDC184 is a gene that has the potential to be a drug target and biomarker for various diseases. Its unique genetic mutation has led to the production of an hyperactive form of the protein, which is involved in the regulation of cell growth, cell division, and apoptosis. Further research is needed to understand the full potential of CCDC184 as a drug target and biomarker.

Protein Name: Coiled-coil Domain Containing 184

The "CCDC184 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCDC184 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets